http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011272740-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e4ccc8d285124f0bf6e541e5c48c177 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B2111-00836 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B28-348 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B28-34 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C09K3-00 |
filingDate | 2011-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2014-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e74471eb16e933c12a4b6a67fa79706b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b76677f95fea871e8e39ba8403a27af7 |
publicationDate | 2014-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2011272740-B2 |
titleOfInvention | Fluorapatite-forming calcium phosphate cements |
abstract | This study reports in vitro and in vivo properties of fluorapatite (FA)-forming calcium phosphate cements (CPCs). Experimental cements contained from (0 to 3.1) mass % of F, corresponding to presence of FA at levels of approximately (0 to 87) mass %. The crystallinity of the apatitic cement product increased greatly with the FA content. When implanted subcutaneously in rats, the in vivo resorption rate decreased significantly with increasing FA content. The cement with the highest FA content was not resorbed in soft tissue, making it biocompatible and bioinert CPC. These bioinert CPCs are candidates for use in useful applications where slow or no resorption of the implant is required to achieve the desired clinical outcome. |
priorityDate | 2010-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.